/**/
HYBRID EVENT: You can participate in person at Barcelona, Spain from your home or work.

6th Edition of

Chemistry World Conference

June 18-20, 2026 | Barcelona, Spain

Chemistry 2026

Personalized and Precision Medicine (PPM) as a unique healthcare model through biodesign-inspired and upgraded business marketing to secure the human healthcare and biosafety

Speaker at Chemistry World Conference 2026 - Sergey Suchkov
N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through biodesign-inspired and upgraded business marketing to secure the human healthcare and biosafety

Abstract:

A new systems approach to subclinical and/or diseased states and wellness resulted in a new trend in the healthcare services, namely, personalized and precision medicine (PPM). To achieve the implementation of PPM concept, it is necessary to create a fundamentally new strategy based upon the biomarkers and targets to have a unique impact for the implementation of PPM model into the clinical practice and pharma & medicinal chemistry bioindustry. In this sense, the translation of discoveries into therapies has not kept pace with medical need. It would be extremely useful to integrate data harvesting from different databanks for applications to provide more tailored measures for the patients and persons-at-risk resulting in improved outcomes. Translational researchers, biodesigners, bio- and chemical engineers, and manufacturers are beginning to realize the promise of PP. Biodesign, bio- and chemical engineering, and nanobiotechnologies are being integrated into diagnostic and therapeutic tools to manage an array of PPM-guided conditions to customize therapeutic management. Partnering and forming strategic alliances between researchers, biodesigners, bio- and chemical engineers, clinicians, business, regulatory bodies and government can help ensure an optimal development program that leverages the Academia and industry experience and FDA’s new and evolving toolkit to speed our way to getting new tools into the innovative markets. Healthcare is undergoing a transformation, and it is imperative to leverage new technologies to sup-port the advent of PPM. It is needed to discover, to develop and to create new (targeted and/or smart/intelligent) drugs being based on design-driven bio- and chemical engineering. In this context and as an example, abzymes are increasingly attractive in a bioindustrial setting as an environmentally friendly alternative to canonical chemical catalysts. To produce the ideal biocatalyst, abzymes often require optimization to increase their catalytic efficiencies and specificities under a particular range of reaction conditions. A number of abzyme engineering strategies are crucial to modify biocatalysts, improving their suitability for large-scale applications in clinical practice and bioindustry. Of great interest are innovative platforms for the diagnosis, prognosis, and precision care of patients and pre-illness persons-at-risk, and integrating state-of-the-art abzyme-related bioengineering and computational tools to create novel biomarkers and therapeutic targets that will open new frontiers in the treatment of chronic diseases. Biocatalyst-related principles are pioneered for creating a new generation of supramolecular nanomaterials in order to develop personalized cancer treatment and vaccines. With the support of nanotechnology, new targeted therapeutic agents and biomaterials, or aid the development of assays for disease biomarkers and identification of potential biomarker-target-ligand (drug) tandems to be used for the targeting, PPM is making phenomenal steps in the future to come. Applications of natural and design-driven biocatalysts as a product of engineering biology and biotech aimed for PPM-guided practice and bioindustry, are highly diverse and will change our world. Advances in healthcare, agritech and food industry include new drugs that reduce environmental harm and foods that are more nutritious and easier to grow. They can improve our food security, helping tackle one of our great global challenges. The latter can also deliver a more sustainable chemical design and industry, drastically reducing the use of poisons for the manufacture of bioproducts. Scaling up from a laboratory reaction to an industrial process is the main challenge for chemical and bioengineers resulting in the optimization at many levels. Moreover, developing and optimizing chemical and biotechnological processes plays a key role in modern society. This is the reason for developing global scientific, clinical, social, and educational projects in the area of PPM and design-driven translational applications to elicit the content of the new trend. The latter would provide a unique platform for collaboration among thought leaders and stakeholders in government, academia, industry, foundations, with an interest in improving the system of healthcare delivery and drug discovery, development, and translation.

Biography:

Dr. Sergey Suchkov was born in Astrakhan, Russia, into a family of medical doctors. He earned his MD from Astrakhan State Medical University in 1980 and his PhD from Sechenov University in 1985. He received advanced training at the NIH (Bethesda, USA), Wills Eye Hospital (Philadelphia, USA), and several British universities under the Royal Society for Immunology. Dr. Suchkov has held numerous academic and leadership roles, including Director of the Division for Clinical Immunology & Immunobiotechnology at MONIKI, and Professor and Chair of the Department for Personalized & Precision Medicine at Sechenov University. He has also served as Vice-Director of the Institute for Biotech & Global Health at RosBioTech National University. Currently, Dr. Suchkov is Professor of Medicine & Immunology and Director of the Center for Biodesign at the N.D. Zelinskii Institute of Organic Chemistry, Russian Academy of Sciences. He also serves as R&D Director at InMedStar (Russia–UAE) and Senior Scientific Advisor to the China Hong Kong Innovation International Business Association. He is an active member of several international scientific organizations, including the New York Academy of Sciences, EPMA, ISPM, PMC, AMEE, ACS, AHA, ARVO, and ISER, and is Secretary General of the United Cultural Convention (UCC), Cambridge, UK.

Watsapp